Absci Prices $100M Offering at 26.5% Discount; Eli Lilly Invests $40M
ABSI has more than doubled off its 52-week low of $2.24 on elevated volume (6.9× avg).
Summary
Absci Corp announced the pricing of a $100 million underwritten public offering at a 26.5% discount, with Eli Lilly & Co. investing $40 million alongside other institutional investors.
Key Events · Financing and Capital Events · ABSI
-
Underwritten Public Offering Priced
Absci Corp entered into an underwriting agreement to sell 13,495,277 shares of common stock, expecting gross proceeds of approximately $100 million and net proceeds of $93.5 million.
-
Significant Discounted Pricing
The shares are being sold at an offering price of $7.41 per share, representing a 26.5% discount compared to the current stock price of $10.08.
-
Strategic Investor Participation
The offering includes a $40 million investment from Eli Lilly & Co., along with participation from other leading financial institutions such as Adage, BVF Partners, Columbia Threadneedle, Invus, and Redmile.
-
Use of Proceeds for ABS-201 Advancement
Net proceeds will primarily fund the advancement of ABS-201, the company's AI-designed anti-PRLR antibody product candidate, across androgenetic alopecia and endometriosis, and for general corporate purposes.
Analysis · ABSI · Industrial Applications And Services
Absci Corp has priced a significant $100 million underwritten public offering at a substantial discount to its current market price. While the 26.5% discount and resulting dilution are negative for existing shareholders, the offering is bolstered by a $40 million investment from Eli Lilly & Co. and participation from other leading institutional investors. This strategic backing, especially following recent positive Phase 1 data for its lead drug candidate ABS-201, provides crucial funding for the advancement of this key pipeline asset and extends the company's operational runway.
At the time of this filing, ABSI was trading at $10.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $2.24 to $11.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.